Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer
Abstract
Immune checkpoint inhibitor therapies are used in the treatment of various cancers to stimulate an antitumor immune response. Checkpoint inhibitors, such as ipilimumab, pembrolizumab, and nivolumab, act by targeting inhibitory pathways and blocking the immune-evading effects of certain malignancies.1Shrimali R.K. Janik J.E. Abu-Eid R. Mkrtichyan M. Khleif S.N. Programmed death-1 & its ligands: promising targets for cancer...
Paper Details
Title
Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer
Published Date
Nov 1, 2018
Journal
Volume
4
Issue
10
Pages
1042 - 1044
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History